Are Oral Selective Estrogen Receptor Degraders Beneficial for Patients With ESR1-Mutated Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer?

被引：1
|
作者：
Okeya, Aoba [1 ]
Shimomura, Akihiko [2 ]
Kitagawa, Dai [1 ]
Shimizu, Chikako [2 ]
机构：
[1] Natl Ctr Global Hlth & Med, Dept Breast Surg Oncol, Tokyo, Japan
[2] Natl Ctr Global Hlth & Med, Dept Breast & Med Oncol, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 28期
关键词：
ESR1; MUTATIONS;
D O I：
10.1200/JCO.24.00992
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Axillary Response to Neoadjuvant Therapy in Node-Positive, Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Patients: Predictors and Oncologic Outcomes
    Orli Friedman-Eldar
    Tolga Ozmen
    Salah James El Haddi
    Neha Goel
    Youley Tjendra
    Susan B. Kesmodel
    Mecker G. Moller
    Dido Franceschi
    Christina Layton
    Eli Avisar
    Annals of Surgical Oncology, 2022, 29 : 4092 - 4101
  • [22] AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
    Tolaney, Sara M.
    Chan, Arlene
    Petrakova, Katarina
    Delaloge, Suzette
    Campone, Mario
    Iwata, Hiroji
    Peddi, Parvin F.
    Kaufman, Peter A.
    De Kermadec, Elisabeth
    Liu, Qianying
    Cohen, Patrick
    Paux, Gautier
    Wang, Lei
    Ternes, Nils
    Boitier, Eric
    Im, Seock-Ah
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (24) : 4014 - +
  • [23] Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trial
    Yu, Ke-Da
    Wu, Si-Yu
    Liu, Guang-Yu
    Wu, Jiong
    Di, Gen-Hong
    Hu, Zhen
    Hou, Yi-Feng
    Chen, Can-Ming
    Fan, Lei
    Tang, Li-Chen
    Shen, Zhen-Zhou
    Wu, Ke-Jin
    Zhuang, Zhi-Gang
    Zhang, Hong-Wei
    Shao, Zhi-Ming
    CANCER, 2019, 125 (13) : 2185 - 2193
  • [24] Tailored neoadjuvant endocrine and chemo-endocrine therapy for postmenopausal patients with estrogen receptor-positive human epidermal growth factor receptor 2-negative primary breast cancer
    Masuda, Norikazu
    Sato, Nobuaki
    Morimoto, Takashi
    Ueno, Takayuki
    Kanbayashi, Chizuko
    Kaneko, Koji
    Yasojima, Hiroyuki
    Saji, Shigehira
    Sasano, Hironobu
    Morita, Satoshi
    Ohno, Shinji
    Toi, Masakazu
    CANCER RESEARCH, 2018, 78 (04)
  • [25] The Utility of Oncotype DX for Adjuvant Chemotherapy Treatment Decisions in Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Node-negative Breast Cancer
    Rizki, Hirah
    Hillyar, Christopher
    Abbassi, Omar
    Miles-Dua, Sascha
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (03)
  • [26] Abemaciclib in Patients with End-Stage Renal Disease and Advanced Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: A Report of 2 Cases
    Gebbia, Vittorio
    CASE REPORTS IN ONCOLOGY, 2022, 15 (01): : 305 - 311
  • [27] Characterization of Estrogen Receptor Low Positive/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
    Li, Ming
    Lv, Hong
    Shui, Ruohong
    Lu, Hongfen
    Yang, Wentao
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 151 - 151
  • [28] Characterization of Estrogen Receptor Low Positive/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
    Li, Ming
    Lv, Hong
    Shui, Ruohong
    Lu, Hongfen
    Yang, Wentao
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 151 - 151
  • [29] Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
    Burris, Howard A., III
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (03) : 201 - 213
  • [30] Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer A Clinical Trial
    Royce, Melanie
    Bachelot, Thomas
    Villanueva, Cristian
    Ozguroglu, Mustafa
    Azevedo, Sergio J.
    Cruz, Felipe Melo
    Debled, Marc
    Hegg, Roberto
    Toyama, Tatsuya
    Falkson, Carla
    Jeong, Joon
    Srimuninnimit, Vichien
    Gradishar, William J.
    Arce, Christina
    Ridolfi, Antonia
    Lin, Chinjune
    Cardoso, Fatima
    JAMA ONCOLOGY, 2018, 4 (07) : 977 - 984
12345